Drugmaker Novartis climbs after guidance rise on sales of blockbuster drugs
Publishing timestamp: 2024-04-23 09:04:46
Summary
Novartis shares climbed after raising full-year guidance following better-than-expected first-quarter results, with net sales and core operating income expected to grow by high single- to low double-digit percentages. CEO highlighted solid growth across major brands and geographies, leading to raised guidance for 2024. Confidence in mid- and long-term growth outlook.
Sentiment: POSITIVE
Keywords: biotech and pharmaceuticals, health care industry, business, novartis ag, pharmaceuticals, earnings, business news, biotechnology,